



(51) International Patent Classification:

A61K 38/02 (2006.01) A61K 38/16 (2006.01)
A61K 38/03 (2006.01) C07K 1/10 (2006.01)
A61K 38/12 (2006.01) C07K 1/107 (2006.01)

(21) International Application Number:

PCT/US2022/030070

(22) International Filing Date:

19 May 2022 (19.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/190,703 19 May 2021 (19.05.2021) US

(71) Applicant: BIOHAVEN THERAPEUTICS LTD.

[US/US]; Biohaven Therapeutics Ltd., 215 Church Street,
New Haven, Connecticut 06510 (US).

(72) Inventors: DUBOWCHIK, Gene M.; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). KAZMIERSKI, Wieslaw; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). PRACITTO, Richard; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). CALDWELL, Reese M.; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: ZUEV, Dmitry; Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTIBODY DRUG CONJUGATES USING MATES TECHNOLOGY FOR DELIVERING CYTOTOXIC AGENTS




Fig. 2

(57) Abstract: Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*